Edition:
United States

Idera Pharmaceuticals Inc (IDRA.OQ)

IDRA.OQ on NASDAQ Stock Exchange Capital Market

1.87USD
15 Dec 2017
Change (% chg)

$-0.08 (-4.10%)
Prev Close
$1.95
Open
$1.95
Day's High
$1.97
Day's Low
$1.84
Volume
3,436,152
Avg. Vol
438,388
52-wk High
$2.87
52-wk Low
$1.30

Chart for

About

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting... (more)

Overall

Beta: 2.18
Market Cap(Mil.): $364.41
Shares Outstanding(Mil.): 194.87
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-U.S. FDA Grants Fast Track Designation For Idera Pharmaceuticals’ IMO-2125 In Combination With Ipilimumab

* U.S. FDA GRANTS FAST TRACK DESIGNATION FOR IDERA PHARMACEUTICALS’ IMO-2125 IN COMBINATION WITH IPILIMUMAB FOR TREATMENT OF PD-1 REFRACTORY METASTATIC MELANOMA Source text for Eikon: Further company coverage:

Nov 29 2017

BRIEF-Idera Pharmaceuticals presents positive translational and clinical data update from ongoing IMO-2125 development program

* Idera Pharmaceuticals Inc presents positive translational and clinical data update from ongoing IMO-2125 development program at the 2017 society for immunotherapy of cancer annual meeting (SITC)

Nov 09 2017

BRIEF-Idera Pharmaceuticals reports Q3 loss per share $0.10

* Idera Pharmaceuticals reports third quarter 2017 financial results and provides corporate update

Nov 06 2017

BRIEF-Idera Pharma announces pricing of public offering of common stock

* Idera Pharmaceuticals announces pricing of public offering of common stock

Oct 26 2017

BRIEF-Idera Pharmaceuticals provides corporate governance update

* Idera Pharmaceuticals provides corporate governance update Source text for Eikon: Further company coverage:

Oct 24 2017

BRIEF-Idera Pharmaceuticals announces proposed public offering of common stock

* Idera Pharmaceuticals announces proposed public offering of common stock

Oct 24 2017

BRIEF-Idera Pharmaceuticals files for‍​ mixed shelf

* Idera pharmaceuticals inc files for‍​ mixed shelf of up to $250 million - sec filing‍​ Source text for Eikon: Further company coverage:

Aug 10 2017

BRIEF-Idera Pharmaceuticals Q2 loss per share $0.14

* Q2 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S

Aug 07 2017

BRIEF-FDA gives "orphan drug" status to Idera's skin cancer drug

* Idera announces FDA orphan drug designation for IMO-2125 for the treatment of melanoma

Jun 22 2017

Earnings vs. Estimates